FindTrial
Sign In

Developing personalized cancer therapy strategy through genomic analysis in liquid biopsy and cancer tissue from metastatic gastrointestinal cancer patients

Developing personalized cancer therapy strategy through genomic analysis in liquid biopsy and cancer tissue from metastatic gastrointestinal cancer patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0003511
Enrollment
210
Registered
2019-02-15
Start date
2018-02-06
Completion date
Unknown
Last updated
2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Pusan National University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: patients with gastrointestinal cancer who have metastasis and who have no other treatment besides chemotherapy are enrolled in this study. Control group: 1) Among patients diagnosed with gastrointestinal cancer histologically, patients without metastasis              2) patients with gastrointestinal diseases without cancer

Exclusion criteria

Exclusion criteria: ECOG 3-4 Patients who refused chemotherapy Under 18 age A patient with intellectual disability Control group: ECOG 3-4, Under 18 age, A patient with intellectual disability

Design outcomes

Secondary

MeasureTime frame
survival days—

Primary

MeasureTime frame
Tissue mutation status and type, mutation and type in blood Next Generation Sequencing test—

Countries

Korea, Republic of

Contacts

Public ContactSung Yong Han

Pusan National University Hospital

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026